Literature DB >> 34001992

Differences in coagulopathy indices in patients with severe versus non-severe COVID-19: a meta-analysis of 35 studies and 6427 patients.

Alberto Polimeni1,2, Isabella Leo1, Carmen Spaccarotella1,2, Annalisa Mongiardo1, Sabato Sorrentino1,2, Jolanda Sabatino1,2, Salvatore De Rosa1,2, Ciro Indolfi3,4,5.   

Abstract

Coronavirus disease 2019 (COVID-19) is a highly contagious disease that appeared in China in December 2019 and spread rapidly around the world. Several patients with severe COVID-19 infection can develop a coagulopathy according to the ISTH criteria for disseminated intravascular coagulopathy (DIC) with fulminant activation of coagulation, resulting in widespread microvascular thrombosis and consumption of coagulation factors. We conducted a meta-analysis in order to explore differences in coagulopathy indices in patients with severe and non-severe COVID-19. An electronic search was performed within PubMed, Google Scholar and Scopus electronic databases between December 2019 (first confirmed Covid-19 case) up to April 6th, 2020. The primary endpoint was the difference of D-dimer values between Non-Severe vs Severe disease and Survivors vs Non-Survivors. Furthermore, results on additional coagulation parameters (platelet count, prothrombin time, activated partial thromboplastin time) were also analyzed. The primary analysis showed that mean d-dimer was significantly lower in COVID-19 patients with non-severe disease than in those with severe (SMD - 2.15 [- 2.73 to - 1.56], I2 98%, P < 0.0001). Similarly, we found a lower mean d-dimer in Survivors compared to Non-Survivors (SMD - 2.91 [- 3.87 to - 1.96], I2 98%, P < 0.0001). Additional analysis of platelet count showed higher levels of mean PLT in Non-Severe patients than those observed in the Severe group (SMD 0.77 [0.32 to 1.22], I2 96%, P < 0.001). Of note, a similar result was observed even when Survivors were compared to Non-Survivors (SMD 1.84 [1.16 to 2.53], I2 97%, P < 0.0001). Interestingly, shorter mean PT was found in both Non-Severe (SMD - 1.34 [- 2.06 to - 0.62], I2 98%, P < 0.0002) and Survivors groups (SMD - 1.61 [- 2.69 to - 0.54], I2 98%, P < 0.003) compared to Severe and Non-Survivor patients. In conclusion, the results of the present meta-analysis demonstrate that Severe COVID-19 infection is associated with higher D-dimer values, lower platelet count and prolonged PT. This data suggests a possible role of disseminated intravascular coagulation in the pathogenesis of COVID-19 disease complications.

Entities:  

Year:  2021        PMID: 34001992     DOI: 10.1038/s41598-021-89967-x

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  27 in total

1.  Clinical Characteristics of Covid-19 in China. Reply.

Authors:  Wei-Jie Guan; Nan-Shan Zhong
Journal:  N Engl J Med       Date:  2020-03-27       Impact factor: 91.245

2.  Biological differentiation of traditional Chinese medicine from excessive to deficient syndromes in AIDS: Comparative microRNA microarray profiling and syndrome-specific biomarker identification.

Authors:  Tingjun Wan; Xiyang Liu; Yue Su; Jiaxi Zou; Xi Wu; Cen Jiang; Chunhui Cao; Mingyue Yao; Yuyu Zhou; Lijun Rong; Baixue Li; Li Wen; Quansheng Feng
Journal:  J Med Virol       Date:  2020-12-17       Impact factor: 2.327

3.  Diagnostic Performance of the Instantaneous Wave-Free Ratio: Comparison With Fractional Flow Reserve.

Authors:  Salvatore De Rosa; Alberto Polimeni; Ricardo Petraco; Justin E Davies; Ciro Indolfi
Journal:  Circ Cardiovasc Interv       Date:  2018-01       Impact factor: 6.546

4.  Characterization of antibody responses to SARS-CoV-2 in convalescent COVID-19 patients.

Authors:  Chuanmiao Liu; Xiaoqi Yu; Chunming Gao; Li Zhang; Hui Zhai; Yanan Hu; Enhui Liu; Qiong Wang; Yu Gao; Dong Wei; Donghua Zhang; Yue Han; Xinxin Zhang
Journal:  J Med Virol       Date:  2020-11-10       Impact factor: 2.327

5.  Corticosteroid treatment in severe COVID-19 patients with acute respiratory distress syndrome.

Authors:  Jiao Liu; Sheng Zhang; Xuan Dong; Zhongyi Li; Qianghong Xu; Huibin Feng; Jing Cai; Sisi Huang; Jun Guo; Lidi Zhang; Yizhu Chen; Wei Zhu; Hangxiang Du; Yongan Liu; Tao Wang; Limin Chen; Zhenliang Wen; Djillali Annane; Jieming Qu; Dechang Chen
Journal:  J Clin Invest       Date:  2020-12-01       Impact factor: 14.808

6.  Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range.

Authors:  Xiang Wan; Wenqian Wang; Jiming Liu; Tiejun Tong
Journal:  BMC Med Res Methodol       Date:  2014-12-19       Impact factor: 4.615

Review 7.  Long-term outcomes of coronary artery bypass grafting versus stent-PCI for unprotected left main disease: a meta-analysis.

Authors:  Salvatore De Rosa; Alberto Polimeni; Jolanda Sabatino; Ciro Indolfi
Journal:  BMC Cardiovasc Disord       Date:  2017-09-06       Impact factor: 2.298

8.  Cardiac involvement of COVID-19: Looking forward to novel discoveries and clinically valuable evidence.

Authors:  Bo Hu; Qing Deng; Qing Zhou
Journal:  Int J Cardiol       Date:  2020-09-01       Impact factor: 4.164

9.  Global, regional, and national estimates of target population sizes for covid-19 vaccination: descriptive study.

Authors:  Wei Wang; Qianhui Wu; Juan Yang; Kaige Dong; Xinghui Chen; Xufang Bai; Xinhua Chen; Zhiyuan Chen; Cécile Viboud; Marco Ajelli; Hongjie Yu
Journal:  BMJ       Date:  2020-12-15

10.  Specific coagulation markers may provide more therapeutic targets in COVID-19 patients receiving prophylactic anticoagulant.

Authors:  Ning Tang; Huan Bai; Dongsheng Xiong; Ziyong Sun
Journal:  J Thromb Haemost       Date:  2020-09       Impact factor: 16.036

View more
  9 in total

Review 1.  Biomarkers during COVID-19: Mechanisms of Change and Implications for Patient Outcomes.

Authors:  Cheng-Han Chen; Sheng-Wen Lin; Ching-Fen Shen; Kai-Sheng Hsieh; Chao-Min Cheng
Journal:  Diagnostics (Basel)       Date:  2022-02-16

Review 2.  Role of Acute Thrombosis in Coronavirus Disease 2019.

Authors:  Derek V Gibbs; Satya S Shreenivas; Kristin M Hudock
Journal:  Crit Care Clin       Date:  2022-03-25       Impact factor: 3.879

Review 3.  Current and novel biomarkers of thrombotic risk in COVID-19: a Consensus Statement from the International COVID-19 Thrombosis Biomarkers Colloquium.

Authors:  Diana A Gorog; Robert F Storey; Paul A Gurbel; Udaya S Tantry; Jeffrey S Berger; Mark Y Chan; Daniel Duerschmied; Susan S Smyth; William A E Parker; Ramzi A Ajjan; Gemma Vilahur; Lina Badimon; Jurrien M Ten Berg; Hugo Ten Cate; Flora Peyvandi; Taia T Wang; Richard C Becker
Journal:  Nat Rev Cardiol       Date:  2022-01-13       Impact factor: 49.421

Review 4.  A central role for amyloid fibrin microclots in long COVID/PASC: origins and therapeutic implications.

Authors:  Douglas B Kell; Gert Jacobus Laubscher; Etheresia Pretorius
Journal:  Biochem J       Date:  2022-02-17       Impact factor: 3.857

5.  Plasma biomarkers associated with survival and thrombosis in hospitalized COVID-19 patients.

Authors:  David Cabrera-Garcia; Andrea Miltiades; Peter Yim; Samantha Parsons; Katerina Elisman; Mohammad Taghi Mansouri; Gebhard Wagener; Neil L Harrison
Journal:  Int J Hematol       Date:  2022-08-22       Impact factor: 2.319

6.  Clinical characteristics and mortality predictors of patients with cancer hospitalized by COVID-19 in a pediatric third-level referral center.

Authors:  Laura-Monserrat Hernández-Regino; Manuel De Jesús Castillejos-López; Arnoldo Aquino-Gálvez; Liliana Velasco-Hidalgo; Alda García-Guzmán; Marco Aguilar-Ortiz; Rocío Cárdenas-Cardos; Luz María Torres-Espíndola
Journal:  Front Pediatr       Date:  2022-07-28       Impact factor: 3.569

Review 7.  The potential role of ischaemia-reperfusion injury in chronic, relapsing diseases such as rheumatoid arthritis, Long COVID, and ME/CFS: evidence, mechanisms, and therapeutic implications.

Authors:  Douglas B Kell; Etheresia Pretorius
Journal:  Biochem J       Date:  2022-08-31       Impact factor: 3.766

8.  Native and activated antithrombin inhibits TMPRSS2 activity and SARS-CoV-2 infection.

Authors:  Lukas Wettstein; Patrick Immenschuh; Tatjana Weil; Carina Conzelmann; Yasser Almeida-Hernández; Markus Hoffmann; Amy Kempf; Inga Nehlmeier; Rishikesh Lotke; Moritz Petersen; Steffen Stenger; Frank Kirchhoff; Daniel Sauter; Stefan Pöhlmann; Elsa Sanchez-Garcia; Jan Münch
Journal:  J Med Virol       Date:  2022-09-03       Impact factor: 20.693

Review 9.  Thromboprophylaxis: balancing evidence and experience during the COVID-19 pandemic.

Authors:  Benjamin Marchandot; Antonin Trimaille; Anais Curtiaud; Kensuke Matsushita; Laurence Jesel; Olivier Morel
Journal:  J Thromb Thrombolysis       Date:  2020-11       Impact factor: 5.221

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.